Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Andrew S. Buchanan"'
Autor:
Jacob P. Thyssen, Thomas Werfel, Sebastien Barbarot, Hamish J.A Hunter, Evangeline Pierce, Luna Sun, Lisa Cirri, Andrew S. Buchanan, Na Lu, Andreas Wollenberg
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Patients who completed the originating studies, BREEZE-AD1 (NCT03334396), BREEZE-AD2(NCT03334422), and BREEZE-AD7 (NCT03733301), were eligible for enrollment in the multicenter,phase-3, long-term extension study BREEZE-AD3 (NCT03334435). M
Externí odkaz:
https://doaj.org/article/c4c894e54c7248608b959261c2cae564
Autor:
Louise Lombard, Mallory Farrar, Wenyu Ye, Yongin Kim, Sarah Cotton, Andrew S. Buchanan, James Jackson, Shivang Joshi
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-16 (2020)
Abstract Background Migraine is a chronic, disabling neurological disease characterized by moderate-to-severe headache pain with other symptoms, including nausea, vomiting, and photophobia. Triptans, while generally effective, are insufficiently effi
Externí odkaz:
https://doaj.org/article/0c9c878ef9a74fe3b6418d92fd56134b
Autor:
Daisy Bridge, Uwe Reuter, Andrew S. Buchanan, Brandy R. Matthews, Ben Rousseau, Louise Lombard, Elizabeth Leroux, Li Shen Loo, Natasha Hopwood
Publikováno v:
Advances in Therapy
Introduction Use of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30–40% of people. We conducted a systematic literature review (SLR) to synthesize definitions, terminology, s
Autor:
Sarah Cotton, Shivang Joshi, James Jackson, Louise Lombard, Wenyu Ye, Yongin Kim, Andrew S. Buchanan, Mallory Farrar
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-16 (2020)
The Journal of Headache and Pain
The Journal of Headache and Pain
Background Migraine is a chronic, disabling neurological disease characterized by moderate-to-severe headache pain with other symptoms, including nausea, vomiting, and photophobia. Triptans, while generally effective, are insufficiently efficacious i
Autor:
Jianing Wang, Erin G Doty, Paul Rizzoli, Emily Liffick, Andrew S. Buchanan, Sherie A. Dowsett, John H. Krege
Publikováno v:
Cephalalgia
Background We assessed the safety profile of lasmiditan, a selective 5-HT1F receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine. Methods SAMURAI and SPARTAN were Phase 3 double-blind studies of patients
Autor:
Joel Raskin, Deborah I. Friedman, John H. Krege, Andrew S. Buchanan, Louise Lombard, Sherie A. Dowsett, Stewart J. Tepper, Josephine K. Asafu-Adjei
Publikováno v:
Headache: The Journal of Head and Face Pain. 59:1052-1062
Trial design SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies conducted in the United States, as well as the United Kingdom and Germany (SPARTAN only). Individuals with migraine were randomized to receive oral lasmiditan 50 m
Autor:
Li Shen Loo, Andrew S. Buchanan, Louise Lombard, Dustin D. Ruff, Dawn C. Buse, Richard B. Lipton, John H. Krege, Thomas E. Melby
Publikováno v:
The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-15 (2020)
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-15 (2020)
Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine dis
Autor:
Andrew S. Buchanan, Robert L. Findling, Joel L. Young, David B. Clemow, Elias H. Sarkis, Linda Wietecha
Publikováno v:
CNS Neuroscience & Therapeutics
Summary Introduction Changes in the magnitude of efficacy throughout 26 weeks of atomoxetine treatment, along with impact of dosing, were evaluated in adults with ADHD from two randomized, double-blind, placebo-controlled studies. Aims Pooled placebo
Autor:
Ekopimo Ibia, Michael Rabbia, Sarah Lipsius, Andrew S. Buchanan, Bruce Binkowitz, Yoko Tanaka
Publikováno v:
Therapeutic Innovation & Regulatory Science. 50:91-100
This article describes follow-up work extended from Tanaka et al (2011) in defining the region in multiregional clinical trials (MRCTs). The previous paper advocated a systematic approach to defining regions and recommended the sponsor to think throu
Publikováno v:
Journal of child and adolescent psychopharmacology. 24(8)
This meta-analysis examined suicide-related events in the acute phases of double-blind, placebo-controlled atomoxetine trials in pediatric and adult patients with attention-deficit/hyperactivity disorder (ADHD).A total of 3883 pediatric and 3365 adul